REReena Engineer

Reena Engineer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reena Engineer has a total of 225 co-authors. Here are the top co-authors by number of shared publications:

  • Avanish Saklani

    Division of Colo‐Rectal and Peritoneal Surface Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute Mumbai India

    14 shared publications
  • Vikas Ostwal

    Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

    14 shared publications
  • Prachi Patil

    Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, 400 094, India

    12 shared publications
  • Supreeta Arya

    Department of Radiology, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India

    10 shared publications
  • Supriya Chopra

    Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India

    10 shared publications
  • Ashwin Desouza

    Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India

    9 shared publications

Latest Publications

  • Open Access

    MRI Based Radiomics as an Imaging Biomarker for Locally Advanced Carcinoma Rectum: Predicting Tumor Response Following Neoadjuvant Chemoradiotherapy as an Organ Preservation Strategy

    byĀ Abhinav Puppalwar, Reena Engineer, Ashish Kumar Jha, Shivakumar Gudi, Rahul Krishnartry, Prashant Nayak, Jai Prakash Agarwal, Jayant S. Goda

    Background: Patients with locally advanced rectal cancer show variable responses to neoadjuvant chemoradiotherapy (NACTRT), making early prediction of treatment response clinically important. Radiomics and machine learning may offer a potential non‐invasive imaging biomarker to identify patients who are more likely to respond to treatment. Aim: We investigated a machine learning‐based radiomic approach to predict tumor response (TR) to NACTRT in patients with adenocarcinoma of the rectum from baseline and post‐NACTRT magnetic resonance imaging (MRI). Methods: One hundred patients with locally advanced rectal cancer, who underwent pre‐ and post‐treatment MRI after NACTRT were included in the study after approval from the institutional ethics committee. One hundred twenty‐four radiomic features were extracted using the TexRad softwareTm, from pre‐ and post‐treatment T2W MRI, which included first‐order, GLCM, and shape features. Features were selected by the recursive feature elimination (RFE) algorithm. Five machine learning classifiers—support vector machine (SVM), random forest (RF), gradient boost (GB), Naive Bayes (NB) and AdaBoost (AB) classifiers were used to develop a prediction model for predicting TR. Results: Five radiomic features were selected using for TR using RFE using RF algorithm. The RF model with 10‐fold internal cross‐validation performed the best for predicting TR. The predictive performance of the RF model for TR was found to be AUC: 0.79 ± 0.15, accuracy: 0.72 ± 0.12, and precision: 0.77 ± 0.10 for the test cohort respectively. Conclusion: RF classifier based radiomic model provided a non‐invasive method to predict TR in patients of carcinoma rectum undergoing NACTRT treatment. The predictive potential of the radiomic features further requires validation in a larger cohort of patients in a multicentric study for clinical translation.

  • Open Access

    Real-World Data on the Practice of Chemoradiation with Select Cohort Consolidation Chemotherapy in High-Risk Locally Advanced Rectal Cancers (SOLAR study)

    byĀ Mounika Yallala, Rahul Krishnatry, Anjali Shah, Prabhat Ghanshyam Bhargava, Anant Ramaswamy, Akshay Baheti, Avanish Saklani, Reena Engineer, Suman K. Ankathi, Mufaddal Kazi, et al.

    Chemoradiation with capecitabine radiotherapy (Cape–RT) has been the standard of care as neoadjuvant treatment in locally advanced rectal cancer (LARC) for more than a decade. However, total neoadjuvant therapy has recently emerged as an alternative with the potential to impact survival outcomes; baseline outcomes with Cape–RT in real-world practice in the Indian context are not well known. Treatment-naive patients with adenocarcinoma on histology and clinical-radiologically diagnosed LARC who received Cape–RT from June 2014 to December 2021 after multidisciplinary discussion were included. Patients received a long course of conventionally fractionated external beam RT (45–50 Gy in 25#) with concurrent oral capecitabine at a dose of 1650 mg/m2/day. Post approximately 6 to 8 weeks of completion of Cape–RT, patients were evaluated clinically and by magnetic resonance imaging pelvis for total mesorectal excision (TME) in the multidisciplinary team meetings. The primary endpoint of the study was event-free survival (EFS), and the secondary endpoint was overall survival (OS) and pathological complete response (PCR) rates. EFS and OS were calculated using the Kaplan–Meier method. A total of 1,189 patients with a median age of 49 years (range: 15–95) were identified and included. A significant proportion of patients had high-risk characteristics, such as T3/T4 disease (94%) and node positivity (90%), and they involved circumferential resection margin (CRM) (51%) at baseline. Signet ring and mucinous histology were seen in 13 and 11% of patients. Two hundred and seventy-six patients (23%) required further consolidation chemotherapy (commonly CAPOX [capecitabine-oxaliplatin] or modified FOLFIRINOX [5-fluorouracil-leucovorin-irinotecan-oxaliplatin]) post-Cape–RT prior to attempting surgery due to either persistent CRM positivity, clinical T4 disease, prostate abutment, sphincter involvement (248 patients, 21%), or extensive bulky disease with poor response (12 patients, 1%). Overall, 14 patients (6%) had an interruption in RT and 22 (8%) in chemotherapy. Post-Cape–RT, with or without chemotherapy, 945 patients (79%) underwent TME. Chemotherapy post-TME was administered in 808 patients (78%). With a median follow-up of 54 months (range: 51.2–57.2), the 3- and 5-year EFS for the entire cohort was 73.2% (95% confidence interval [CI]: 70.6–75.8) and 64.3% (95% CI: 61.1–67.5), respectively, while the estimated 3- and 5-year OS was 81.3% (95% CI: 78.9–83.7) and 73% (95% CI: 70–76), respectively. On multivariate analysis, the presence of higher T stage (p < 0.001) and signet ring histology (p = 0.004) predicted inferior OS. Real-world data in a less-resourced setting concurs with published prospective and Western real-world data. This provides confidence in implementing consolidation chemotherapy in total neoadjuvant settings in countries with fewer resources. The study was approved by the Institutional Review Board (IRB) and Ethics Committee (EC) (IEC/1116/1799/001) at Tata Memorial Hospital, Mumbai, Maharashtra, India. None. Received: 05 October 2024 Accepted: 06 March 2025 Article published online: 03 April 2025 Ā© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • Anal Canal Cancer

    byĀ Shirley Lewis, Reena Engineer, Ashwin Desouza

  • Open Access

    Evaluation and Management of Unresectable Hepatocellular Carcinoma: Multidisciplinary Indian Consensus Statements from a Delphi Panel

    byĀ Anant Ramaswamy, Akash Shukla, Reena Engineer, Sridhar Sundaram, Sujay Srinivas, Suyash Kulkarni, Shraddha Patkar, Sanjay Baijal, Aditya Kale, Akhil Kapoor, et al.

    India, like many parts of Asia, likely faces a high burden of hepatocellular carcinoma (HCC), though large-scale data on etiology, presentation, and outcomes are lacking. There appears to be a predominance of unresectable, advanced-stage HCC at presentation in India with variable level of expertise in India to manage these scenarios. This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by treating clinicians. A multidisciplinary panel of medical oncologists, gastroenterologists, hepatologists, interventional radiologists, and hepatobiliary surgical oncologists held a meeting in June 2022 and reviewed the evidence available for management of HCC. The meeting concentrated on the recognition and management of HCC not amenable to surgical approaches in the Indian context. A literature review of these aspects of management was conducted and consensus statements with level of evidence and grades of recommendation were prepared by individual specialists in each field. Statements were evaluated by the modified Delphi method. The panel comprising 22 experts formulated 40 consensus statements with regard to defining unresectable HCC, optimization of underlying conditions prior to management, rationale use of various liver-directed therapies (LDTs) in unresectable HCC, and systemic therapeutic options in this group of patients. Our consensus statements offer practical, yet evidence-based management guidelines for treating unresectable HCC in the Indian context. There is an emphasis on the crucial need for combining available approaches for LDT, even if less well studied though possibly effective, with standard systemic therapy.

  • Open Access

    Non-operative management in low-lying rectal cancers undergoing chemoradiation

    byĀ Debanjali Datta, Reena Engineer, Avanish Saklani, Ashwin D’SOuza, Akshay Baheti, Suman Kumar, Rahul Krishnatry, Vikas Ostwal, Anant Ramaswamy, Prachi Patil

    Purpose: To evaluate the outcomes of post-neoadjuvant chemoradiation (NACTRT) wait-and-watch Strategy (WWS) in distal rectal cancers. Materials and Methods: All consecutive patients from December 2012 to 2019 diagnosed with distal rectal tumors (T2-T4 N0-N+) having a complete or near-complete response (cCR or nCR, respectively) post-NACTRT and wishing for the non-surgical treatment option of WWS were included in this study. Patients were observed with 3 monthly magnetic resonance imaging (MRIs), sigmoidoscopies, and digital rectal examination for 2 years and 6 monthly thereafter. Organ preservation rate (OPR), local regrowth rate (LRR), non-regrowth recurrence-free survival (NR-RFS) and overall survival (OAS) were estimated using the Kaplan–Meier method, and factors associated with LRR were identified on univariate and multivariate analysis using the log-rank test ( P < 0.05 significant). Results: Sixty-one consecutive patients post-NACTRT achieving cCR[44 (72%)] and nCR[17 (28%)], respectively, were identified. All patients received pelvic radiotherapy at a dose of 45–50Gy conventional fractionation and concurrent capecitabine. An additional boost dose with either an external beam or brachytherapy was given to 39 patients. At a median follow-up of 39 months, 11 (18%) patients had local regrowth, of which seven were salvaged with surgery and the rest are alive with the disease, as they refused surgery. The overall OPR, NR-RFS, and OS were 83%, 95%, and 98%, respectively. Seven (11%) patients developed distant metastasis, of which six underwent metastatectomy and are alive and well. LRR was higher in patients with nCR versus cCR ( P = 0.05). Conclusion: The WWS is a safe non-operative alternative management for selected patients attaining cCR/nCR after NACTRT with excellent outcomes.


  • Open Access

    Translation and Pilot Validation of Hindi, Marathi, and Bangla Translation of Quality-of-Life EORTC Radiation Proctitis Module (PRT-20) for Routine Clinical Use

    byĀ Revathy Krishnamurthy, Rahul Krishnatry, Devankshi Rane, Purva Pawar, Debanjan Chakraborty, Utpal Gaikwad, Suman Ghosh, Aasma Siddiqui, Debanjali Datta, Akanksha Anup, et al.

    The aim of this study was to translate and validate the European Organization for Research and Treatment for Cancer (EORTC) ā€œRadiation Proctitisā€ (PRT-20) module in Hindi, Marathi, and Bangla languages. The EORTC PRT-20 was translated into Hindi, Marathi, and Bangla using EORTC guidelines. Two separate translators first translated the original questionnaire into the three regional languages, following which a reconciled forward translation was compiled. This reconciled version in each language was then back-translated into English by two other translators. This back-translated version was then compared with the original the EORTC questionnaire for correctness, and the preliminary questionnaires were formed in all three languages. The EORTC translation unit approved the questionnaires. The preliminary questionnaires were administered to 30 patients (10 for each language) diagnosed with rectal or anal canal cancer who had received pelvic radiotherapy and were at risk of developing PRT. None of the patients had seen the questionnaire before. After filling out the questionnaire, each patient was interviewed for difficulty in answering, confusion, understanding, or if any of the questions were upsetting and if patients would have asked the question differently. No changes were suggested for Marathi and Bangla translations. Two modifications were suggested in the Hindi translation, which was then retested in five patients and finalized. All the suggestions were incorporated into the preliminary questionnaires, which were sent back to the EORTC for final approval. After reviewing the entire report of pilot testing for the translated quality-of-life questionaire-PRT-20 in three languages, it was approved by the EORTC translation unit. The translated questionnaires were reliable, with Cronbach α values of 0.767, 0.799, and 0.898 for Hindi, Marathi, and Bangla, respectively. The Hindi, Marathi, and Bangla translations of PRT-20 have been approved by the EORTC and can be used in routine clinical practice.

  • MRI in rectal cancer patients on ā€˜watch and wait’: patterns of response and their evolution

    byĀ Aashna Karbhari, Akshay D Baheti, Suman K Ankathi, Purvi D Haria, Amit Choudhari, Aparna Katdare, Amrita Guha, Suyash Kulkarni, Avnish Saklani, Reena Engineer, et al.

    Purpose Evaluate MR patterns of response and their evolution in rectal cancer patients on watch and wait (WW). Methods We retrospectively reviewed 337 MRIs of 60 patients (median follow-up: 12 months; range: 6–49 months). Baseline MRIs (available in 34/60 patients) were evaluated for tumor morphology, location, thickness, circumferential involvement, nodal status and EMVI. First post-treatment MRIs (in all patients) were additionally evaluated for pattern of response on T2 and DWI. Change in post-treatment scar thickness and scar depth angle between the first and second post-treatment scans was also evaluated. Evolution of the response pattern/recurrence were evaluated till the last available scan. Results On the baseline scans, 20/34 (59%) patients had polypoidal tumor with 12/20 having ≤ 25% circumferential wall involvement. We saw five patterns of response-normalized rectal wall (2/60–3%), minimal fibrosis (23/60–38%), full thickness fibrosis (16/60–27%), irregular fibrosis (11/60–18%) and split scar (6/60–10%), with 2/60 (3%) showing possible residual disease. On the first post-treatment scans, 12/60 (20%) had restricted diffusion, with 3/12 having persistent restriction till last follow-up. Post-treatment fibrosis/split scar remained stable in 44/60 (73%) cases and improved further in the rest. 9/60 (15%) patients developed regrowth/recurrence. Patients with recurrence had < 10 mm scar thickness and < 21° change in scar angle between the first and second post-treatment MRIs. Conclusion Most patients on WW protocol developed minimal or full thickness fibrosis, majority of which remained stable on follow-up. Graphical abstract


  • Extramural vascular invasion as an independent prognostic marker in locally advanced rectal cancer: propensity score match pair analysis

    byĀ Sonz Paul, Supreeta Arya, Smruti Mokul, Akshay Baheti, Suman Kumar, Anant Ramaswamy, Vikas Ostwal, Supriya Chopra, Avanish Saklani, Ashwin Desouza, et al.

    Background In rectal cancers, presence of extramural vascular invasion on MRI (mrEMVI) is associated with poor survival. The independent influence of mrEMVI in the presence of other prognostic factors has not been previously analyzed using match pair analysis. Patients and methods Consecutive 92 patients having mrEMVI at presentation treated between January 2016 and December 2018 were matched with 92 patients (1:1) without mrEMVI. Matching parameters were T stage, mesorectal fascia involvement, and tumor differentiation. The presence and absence of mrEMVI were correlated to outcomes. An event was defined as locoregional failure or distant metastasis or poor response to chemoradiation rendering the rectal tumor as inoperable. Results At 3 years, in the mrEMVI-positive cohort, 59% had an event and in the mrEMVI-negative cohort, 45% had an event (p = 0.026). Local control was 90.2% (12recurrences in 122 who underwent surgery), two recurrences in the mrEMVI-positive cohort and ten patients in the mrEMVI-negative cohort, which missed statistical significance (p = 0.06). Distant metastasis-free survival was significantly worse in the mrEMVI-positive cohort versus the mrEMVI-negative cohort (58.2% vs. 69.4%) (p = 0.022). Similarly, Overall survival was significantly inferior in mrEMVI-positive cohort compared to the mrEMVI-negative cohort (57% vs. 72.4%) (p = 0.02). The multivariate regression analysis confirmed the independent predictive value of mrEMVI. Conclusion Extramural vascular invasion detected through MRI is an independent risk factor for distant metastasis in the locally advanced carcinoma rectum. Aggressive treatment regimens like total neoadjuvant treatment should be considered in these cases pending randomized control studies.


  • Open Access

    Treatment of Metastatic Colorectal Cancers in Resource-Constrained Low- and Middle-Income Countries (LMICS) Scenario—Outcomes, Practice Patterns, and Commentary on Treatment Costs

    byĀ Anant Ramaswamy, Vasu Babu, Rushabh Kothari, Ram Abhinav, Ashwin Desouza, Pradeep Ventrapati, Amit Kumar, Akhil Kapoor, Shasanka Das, Reena Engineer, et al.

    Introduction The overall survival (OS) of metastatic colorectal cancers (mCRCs) in clinical practice and resource-constrained low- and middle-income countries (LMICS) like India is not known. Materials and Methods Data of patients with mCRC treated between January 2013 and August 2017 were accessed from a prospectively maintained database. Demographics, disease characteristics, chemotherapeutic regimens, use of monoclonal antibodies, and survival outcomes in treated patients were collected and analyzed. Costs of treatment options as off 2017 were also interpreted. Results The data of 403 patients satisfied prespecified inclusion criteria and were included for analysis. The median age of the cohort was 48 years (range: 17–86) with a predominance of rectal cancers (63.3%), liver alone metastases (47.1%), and resected primary (69.7%). Signet ring histology was present in 82 patients (20.3%). The most commonly used first-line regimen (CT1) was modified capecitabine-oxaliplatin (53.3%). Two hundred and nineteen patients (54.3%) received second-line systemic therapy (CT2). Patients received a median of two lines of therapy (range: 1–6). MoAbs were used by 48 patients (13.4%) with CT1 and 34 patients (15.5%) with CT2. Median OS of the entire cohort was 17.61 months (95% confidence interval: 15.48–19.74), which was within the predicted range, as per investigator hypothesis. The presence of signet ring histology (p<0.001), raised carcinoembryonic antigen at baseline (p=0.017), and the absence of a resected primary (p<0.001) predicted inferior median OS. Conclusions Survival of patients with mCRC in a resource-constrained LMIC scenario like India is approximately 12 to 15 months lower than published trial data. Limited access to targeted therapy and newer expensive treatment options due to financial constraints may contribute to this disparity.


  • Open Access

    Impact of the First Wave of COVID-19 Pandemic on Radiotherapy Practice at Tata Memorial Centre, Mumbai: A Longitudinal Cohort Study

    byĀ Anil Tibdewal, Rima Pathak, Anuj Kumar, Sachith Anand, Sarbani Ghosh Laskar, Rajiv Sarin, Supriya Chopra, Reena Engineer, Siddharth Laskar, Vedang Murthy, et al.

    PURPOSE: Delivery of cancer care during the pandemic required adopting various changes in the standard management. We analyzed the impact of the first wave of the COVID-19 pandemic on radiation oncology treatment practices at Tata Memorial Hospital in India.MATERIALS AND METHODS: From March 1 to October 31, 2020, all consecutive patients who attended the radiation oncology department for radiotherapy treatment were included in this study. Electronic medical records, patient files, and telephonic consult were used to collect patient's data including changes in the standard treatment practice, COVID-19 testing and its results, and subsequent impact on radiotherapy treatment. Comparison was done with the same period data of 2019 for the number of the caseload, radiotherapy regimen, referral rates, and noncompliance rates.RESULTS: Our study included 4,256 patients with a median age of 52 years (interquartile range 41-61 years). There was a significant drop in the new-patient registrations (approximately 63%), radiotherapy consultations (44.9%), and referrals to other centers (27.8%). The reduction in the caseload was highest for genitourinary cases (–58.5%) and the lowest for breast cases (–11.5%) when compared with the 2019 cohort. Among those treated with radical intent, the noncompliance rate was 15%. Hypofractionation was the commonly adopted regimen across all sites. Compared with 2019, the maximum reduction in the average fractions per patient was seen in the breast cancer cases (–8.2 fraction), followed by genitourinary cases (–4.9 fraction). Of the 27.8% of patients tested for COVID-19, 13.4% turned positive and 3.4% died due to the disease.CONCLUSION: The COVID-19 pandemic adversely affected the number of radiotherapy consultations and treatments at our institute. However, our department offered uninterrupted services despite grave challenges. Hypofractionated regimen was used across disease sites to minimize patient visits and allow planned treatment completion. Radiotherapy was delivered safely, and patients experienced low rates of COVID positivity during radiotherapy and even lower mortality.